Ryan Specialty Holdings, Inc.
RYAN
$44.47
-1.20%
Ryan Specialty Holdings, Inc. is an international specialty insurance intermediary that provides wholesale brokerage and delegated underwriting authority products and services, including distribution, underwriting, product development, administration, and risk management, across property, casualty, professional lines, transportation, personal lines, workers compensation, and employee benefits. The company operates as a leading player in the specialty insurance market, distinguishing itself through its expertise in complex and niche risks, serving insurance brokers, agents, and carriers. Currently, the investor narrative centers on the company's recent stock price volatility, with a significant drawdown over the past year followed by a sharp recovery in recent months, amid broader market selloffs and potential buying opportunities for patient investors.…
RYAN
Ryan Specialty Holdings, Inc.
$44.47
Investment Opinion: Should I buy RYAN Today?
Based on the analysis, RYAN is rated a Hold. The consensus is a Buy with an average target of $45.875, implying only 3.9% upside, which is modest. The thesis is that while the company has strong growth prospects, the current price already reflects much of the expected improvement, and the high leverage and thin margins introduce significant risk. Supporting evidence includes the forward PE of 18.57, which is reasonable if EPS reaches $2.61, but the trailing PE of 103.26 and the 27.8% 1-year decline suggest the market is skeptical. The stock has a gross margin of 90.6% and operating margin of 20.5%, indicating a solid business model, but the net margin of 2.1% shows that interest and other costs are eating into profits. The main risks are the high debt load, potential earnings disappointment, and the stock's poor relative performance. This Hold would upgrade to Buy if the stock pulls back to around $35 (near the low target) or if revenue growth accelerates above 30%, and downgrade to Sell if forward PE exceeds 25 or if the company misses earnings estimates. Overall, RYAN appears fairly valued relative to its forward earnings but overvalued on trailing metrics, making it a hold for now.
Sign up to view all
RYAN 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The stock's valuation on forward earnings is attractive, but the high leverage and thin current margins introduce significant risk. The consensus Buy rating and modest upside suggest that the stock is fairly valued at current levels. To upgrade to bullish, we would need to see evidence of accelerating revenue growth or a reduction in debt. Conversely, a downgrade to bearish would be warranted if the company misses earnings or if macro conditions deteriorate, leading to a de-rating. Overall, the risk-reward is balanced, and the stock is likely to trade in a range until clearer signals emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Ryan Specialty Holdings, Inc.'s 12-month outlook, with a consensus price target around $49.84 and implied upside of +12.1% versus the current price.
Average Target
$49.84
0 analysts
Implied Upside
+12.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$34 - $76
Analyst target range
Ryan Specialty is covered by 16 analysts, with a consensus recommendation of 'buy' and a mean recommendation score of 2.32 (where 1 is strong buy and 5 is sell). The average target price is $45.875, which implies an upside of approximately 3.9% from the current price of $44.16. The distribution of ratings is not provided, but the overall sentiment leans bullish, albeit with a modest upside expectation.
Bulls vs Bears: RYAN Investment Factors
Ryan Specialty presents a mixed picture: strong forward growth expectations and a buy consensus are countered by high leverage, poor recent performance, and a rich trailing valuation. The bull case hinges on the company delivering the projected 25% revenue growth and a dramatic earnings expansion, which would justify the forward PE of 18.6. The bear case is that the high debt and low current margins make the earnings growth uncertain, and the stock's underperformance relative to the market suggests persistent headwinds. Currently, the evidence slightly favors the bulls due to the strong analyst backing and forward valuation, but the key tension is whether the projected earnings surge will actually materialize, as any shortfall could trigger a sharp selloff given the high expectations.
Bullish
- Strong Revenue Growth Expected: Analysts project revenue to grow from approximately $3.05 billion (implied by PS ratio) to $3.81 billion next fiscal year, a ~25% increase. This robust top-line expansion is driven by specialty insurance demand and the company's niche positioning.
- Significant Forward Earnings Upside: Forward PE of 18.57 versus trailing PE of 103.26 indicates the market expects a dramatic earnings surge, with estimated EPS of $2.61 for next year. This implies a sharp improvement in profitability, making the stock look reasonably valued on forward earnings.
- Analyst Consensus is Buy: With 16 analysts, the consensus recommendation is 'buy' (mean score 2.32), and the average target price of $45.875 is 3.9% above the current price. This suggests professional investors see further upside, albeit modest.
- High Gross Margin and Operating Margin: Gross margin is 90.6% and operating margin is 20.5%, reflecting a highly scalable business model with strong pricing power. These margins are typical of asset-light intermediaries and support future earnings growth.
Bearish
- High Debt-to-Equity Ratio: Debt-to-equity is 5.45, indicating significant leverage. This financial risk could amplify earnings volatility and constrain flexibility, especially if interest rates remain elevated or cash flows weaken.
- Poor 1-Year Performance vs. Market: RYAN is down 27.8% over the past year while the S&P 500 is up 18.2%, underperforming by 46 percentage points. This suggests persistent negative sentiment and potential structural issues.
- Low Net Margin and High Payout: Net margin is only 2.1%, and the payout ratio is 98.3%, meaning nearly all earnings are paid out as dividends. This leaves little retained earnings for growth or debt reduction, and the dividend yield is just 0.95%.
- Valuation Premium on Trailing Earnings: Trailing PE of 103.26 is extremely high, indicating the stock is expensive based on current earnings. If the expected earnings growth fails to materialize, the stock could face significant de-rating.
RYAN Technical Analysis
The prevailing price trend for Ryan Specialty is a recovery from a significant downtrend, as evidenced by a 1-year price change of -27.83%, yet the stock has rebounded strongly from its 52-week low of $29.28. As of the latest close, the stock is trading at $44.16, which is approximately 72% of the way from the 52-week low to the 52-week high of $61.05, indicating a substantial recovery but still below the highs. This positioning suggests that while the stock has regained ground, it remains in a corrective phase relative to its prior peak, with potential for further upside if momentum persists.
Beta
0.57
0.57x market volatility
Max Drawdown
-56.2%
Largest decline past year
52-Week Range
$29-$61
Price range past year
Annual Return
-22.5%
Cumulative gain past year
| Period | RYAN Return | S&P 500 |
|---|---|---|
| 1m | +7.0% | +2.8% |
| 3m | +42.0% | +4.2% |
| 6m | -6.4% | +11.3% |
| 1y | -22.5% | +21.5% |
| ytd | -12.1% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RYAN Fundamental Analysis
Ryan Specialty's revenue trajectory is not directly provided in the quarterly financials, but the company's market cap of $6.57 billion and PS ratio of 2.15 imply a revenue base of approximately $3.05 billion, based on the current price. The estimated revenue for the next fiscal year is $3.81 billion, indicating an expected growth rate of about 25% year-over-year, which suggests a robust growth trajectory. However, the lack of historical quarterly revenue data limits a detailed multi-quarter trend analysis, but the forward estimates from analysts point to continued expansion.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RYAN Overvalued?
Given that Ryan Specialty has a positive net income (EPS of $0.0096), the primary valuation metric selected is the PE ratio. The trailing PE is 103.26, while the forward PE is 18.57, indicating that the market expects significant earnings growth in the coming year, as the forward PE is substantially lower. This gap suggests that the market is pricing in a sharp improvement in profitability, which is consistent with the estimated EPS of $2.61 for the next fiscal year, a dramatic increase from the current EPS.
PE
103.3x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Ryan Specialty carries a high debt-to-equity ratio of 5.45, which amplifies its exposure to interest rate changes and could strain cash flows if earnings underperform. The net margin is thin at 2.1%, and the payout ratio of 98.3% leaves little room for reinvestment or debt reduction, increasing financial fragility. Additionally, the trailing PE of 103.26 implies that the stock is priced for perfection; any earnings miss could lead to a severe de-rating. The company's reliance on continued growth to justify its valuation is a key financial risk, as a slowdown in the specialty insurance market could quickly erode investor confidence.
FAQ
The key risks of holding RYAN include: 1) Financial risk from high leverage, with a debt-to-equity ratio of 5.45, which could strain cash flows if interest rates rise or earnings decline. 2) Valuation risk, as the trailing PE of 103.26 leaves little room for error; any earnings miss could lead to a sharp selloff. 3) Market risk, as the stock has underperformed the S&P 500 by 46 percentage points over the past year, indicating negative sentiment. 4) Company-specific risk, such as dependence on the specialty insurance market, which could be affected by regulatory changes or competitive pressures. The most severe risk is a combination of these factors leading to a drop to the 52-week low of $29.28, a 34% downside from the current price.
The 12-month forecast for RYAN is based on three scenarios. The bull case (30% probability) targets $55-$76, driven by strong growth and multiple expansion. The base case (50% probability) targets $42-$48, aligning with the analyst average of $45.875. The bear case (20% probability) targets $29-$34, if growth disappoints. The most likely scenario is the base case, which assumes the company meets its growth targets but the stock remains range-bound due to high leverage and macro uncertainties. Investors should watch for earnings reports and revenue growth to confirm the trajectory.
RYAN's valuation is mixed. On a trailing basis, the PE of 103.26 is extremely high, suggesting the stock is overvalued relative to current earnings. However, on a forward basis, the PE of 18.57 is more reasonable, indicating that the market expects significant earnings growth. The PS ratio of 2.15 is moderate for a growth company, and the EV/EBITDA of 12.38 is in line with industry norms. Compared to its own history, the stock is trading well below its 52-week high of $61.05, but it has recovered from the low. Overall, the stock appears fairly valued if the growth projections are met, but overvalued if they are not. The market is pricing in a sharp improvement in profitability, and if that fails to materialize, the stock could be considered overvalued.
RYAN is a good buy for investors who believe in the company's growth story and are comfortable with the risks. The analyst consensus is Buy, and the average target price of $45.875 offers a modest 3.9% upside. The forward PE of 18.57 is reasonable if the projected EPS of $2.61 is achieved, but the trailing PE of 103.26 and the high debt-to-equity ratio of 5.45 are concerning. The stock has been volatile, with a 52-week range of $29.28 to $61.05, so it is not for the faint-hearted. For long-term investors with a high risk tolerance, it could be a good buy at current levels, but for conservative investors, it may be better to wait for a pullback or more evidence of earnings growth.
RYAN is more suitable for long-term investment, given its growth potential and the expectation of significant earnings expansion. The stock is volatile, with a beta that has led to a max drawdown of -56.8%, making it risky for short-term traders. The company pays a small dividend (yield 0.95%), but the payout ratio is high, so dividend growth may be limited. For long-term investors, the forward PE of 18.57 suggests that if the company achieves its EPS target of $2.61, the stock could appreciate significantly. A minimum holding period of 3-5 years is recommended to allow the growth story to play out and to ride out volatility. Short-term traders might find opportunities in the stock's swings, but the high risk and low upside to the average target make it less attractive for short-term gains.